Market Scenario :
HIV prevalence in Africa, specifically in Southern region is very high as compared to North African region. Approximately 1 out of 4 is suffering from HIV. Southern and Eastern region of Africa has one of the highest prevalence rate of HIV, about 19 million people have HIV. While HIV prevalence is low in North Africa but the number of cases of HIV are increasing rapidly. There is no cure for HIV but drugs manufacturing companies are investing huge money in R&D to develop drugs for HIV. Over 3000 patients were died in sub Saharan Africa due to HIV in 2015. Following 10 countries from Africa consists of 80% of total HIV burden which are South Africa, Kenya, Malawi, Ethiopia, Mozambique, United Republic of Tanzania, Nigeria, Uganda, Zimbabwe and Zambia.
Middle East and Africa HIV Diagnosis & Treatment Market is growing moderately. Middle East and Africa HIV Diagnosis & Treatment Market is expected to grow at a CAGR of 3.3% and expected to reach US$ 2.07 billion by 2023 from US$ 1.65 billion in 2016.
Intended Audience
- Hospitals and Clinics
- HIV Diagnosis & Treatment drugs manufacturers
- HIV Diagnosis & Treatment drugs suppliers
- Government and Independent Regulatory Authorities
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Medical Research Laboratories
- Potential Investors
Key Players for Middle East and Africa HIV Diagnosis & Treatment Market:
Some of the key players in HIV Diagnosis & Treatment Market Size are: Abbott Laboratories (US), Boehringer Ingelheim GmbH (Germany), Bristol-Myers Squibb Company (US), Cipla Inc. (India), F. Hoffmann-La Roche Ltd (Switzerland), Gilead (US), GlaxoSmithKline plc. (UK), Johnson & Johnson Services, Inc.(US), ViiV Healthcare group of companies (UK), Merck & Co., Inc. (US).
Segments:
Middle East and Africa HIV Diagnosis & Treatment Market has been segmented on the basis of diagnosis which comprise ELISA Test, Saliva Tests, Viral Load Test, Western Blot, and Others. On the basis of treatment, market is segmented into Protease inhibitors (PIs), Non-nucleoside reverse transcriptase inhibitors (NNRTIs), Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs), Entry or fusion inhibitors, Integrase inhibitors, and others.
Regional Analysis of Middle East and Africa HIV Diagnosis & Treatment Market:
Considering the scenario of the Middle East and African HIV Diagnosis & Treatment market, Africa is believed to be the largest market for HIV Diagnosis & Treatment. Moreover, the Rest of Middle East and Africa is growing and it is the second largest market for Middle East and Africa HIV Diagnosis & Treatment. On the other hand, UAE market is expected to grow at significant rate in the Middle East and Africa HIV Diagnosis & Treatment during the forecasted period. Saudi Arabia is likely to have a limited but moderate growth in the market.
The report for Middle East and Africa HIV Diagnosis & Treatment Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
Read More @ https://www.marketresearchfuture.com/reports/hiv-diagnosis-treatment-market-2990
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Anti-Viral Drugs Market OverviewGlobal anti-viral drugs market is expected to grow at a CAGR of 6.9% and attain USD 62.67 Bn by the end of the forecast period of 2016-2022, asserts Market Research Future (MRFR) in an exhaustive research report.
Infectious diseases such as influenza, herpes, hepatitis C are among the leading causes of death worldwide.
The incidence rate of HIV has seen a surge in recent years, especially in the developing countries which indicate high demand for anti-viral drugs.
The paucity of new anti-viral drugs will be addressed by this drug development which will eliminate the reliance on the limited number of drugs.
Besides, growing focus on R activities provides ample opportunities for market growth.
Anti-Viral Drugs Market Regional AnalysisThe Americas, Europe, Asia Pacific, and Middle East & Africa are the key markets for antiviral drugs.
The market segment of anti-viral drugs is driven by factors such as rise in healthcare expenditure, growing research and development investment, emergence of virus life-threatening diseases like bird flu, strong development pipeline and increasing incidence rates of viral infections particularly HIV.
Strong research pipeline coupled with rise in research and development investment will be the market driver of the future.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/2454The constraints on the market include side effects associated with treatment, the cost of the therapy and poor efficacy and effectiveness of the drugs.SegmentationThe global anti-viral drugs market has been segmented based on application and mechanism of action.
By application, the market has been segmented into hepatitis, HIV/AIDS, herpes, influenza and others.
By mechanism of action, the market has been segmented into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others.Regional AnalysisThe Americas, Europe, Asia Pacific, and Middle East & Africa are the key markets for antiviral drugs.
The Europe market is driven by the presence of a robust healthcare sector and high investment in R activities.
Growing prevalence of viral infections in the developing economies of the region coupled with the outlay of massive amounts on healthcare facilities supports the growth of the Asia Pacific market.
The global hospital acquired infections therapeutic market size is expected to reach USD 12.52 billion by 2028 according to a new study by Polaris Market Research.
The report “Hospital Acquired Infections Therapeutic Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Antibacterial Drugs {Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, Others}, Antiviral Drugs, Antifungal Drugs); By Infection Type; By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.For instance, as per the market study done by Globocan, in 2018, there were 4,285,033 new cancer cases in China.
Thus, with increased hospital admissions, the market demand for hospital acquired infections therapeutics is bound to rise.
Market participants such as Merck, Abbott Laboratories, Pfizer Inc., GlaxoSmithKline Plc., Bayer AG, AbbVie Inc., F. Hoffmann-La Roche Ltd, Daiichi Sankyo Company, Limited and Allergan Plc.Get Sample PDF @ https://www.polarismarketresearch.com/industry-analysis/hospital-acquired-infections-therapeutic-market/request-for-sample The study objectives are:To analyze and research the global Hospital Acquired Infections Therapeutic Market capacity, production, value, consumption, status and forecast;To focus on the key Hospital Acquired Infections Therapeutic Market manufacturers and study the capacity, production, value, market share and development plans in next few years.To focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.To define, describe and forecast the market by type, application and region.To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.To identify significant trends and factors driving or inhibiting the market growth.To analyze the opportunities in the market for stakeholders by identifying the high growth segments.To strategically analyze each submarket with respect to individual growth trend and their contribution to the market.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.To strategically profile the key players and comprehensively analyze their growth strategies.Hospital Acquired Infections Therapeutic, by Regional Outlook (Revenue – USD Million, 2016 – 2028)North AmericaS.CanadaEuropeFranceGermanyUKItalySpainNetherlandsAustriaAsia PacificChinaIndiaJapanMalaysiaSouth KoreaIndonesiaCentral & South AmericaMexicoBrazilArgentinaMiddle East & AfricaUAESaudi ArabiaIsraelSouth AfricaGet Special Discount On this Research Report @ https://www.polarismarketresearch.com/industry-analysis/hospital-acquired-infections-therapeutic-market/request-for-discount-pricingAbout Polaris Market ResearchPolaris Market Research is a Middle East market research and consulting company.
The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.Contact Us:Polaris Market ResearchPhone: 1–646–568–9980Email: [email protected]: www.polarismarketresearch.com
HIV Drugs Market:WiseGuyReports.com adds “Global HIV Drugs Market Research Report 2020-30” reports to its database.Executive SummaryThe global HIV drugs market is expected to grow from $27 billion in 2019 to about $30.5 billion in 2020 due to an increase in demand for such drugs for the treatment of Covid-19 patients.
Currently, several countries are evaluating and using antiretroviral drugs (for instance lopinavir boosted with ritonavir (LPV/r)), for treating corona virus infection.The HIV drugs market consists of sales of Human Immunodeficiency Virus (HIV) drugs used for the treatment of HIV infection/AIDS.
The market consists of revenue generated by the antiretroviral drug companies manufacturing the anti-retroviral drugs such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry and fusion inhibitors, integrase inhibitors, and protease inhibitors (PIs) for the treatment of HIV infection.Request Free Sample Report @ https://www.wiseguyreports.com/sample-request/5226499-hiv-drugs-global-market-report-2020-30-covidNorth America was the largest region in the HIV drugs market in 2019.Side Effects of HIV Drugs have always been a major challenge in antiretroviral therapy.
Antiretroviral drugs are used to treat HIV and AIDS as these drugs help lower viral load, control the growth of the virus, boosts the ability to fight infections, prevent HIV transmission to others and help stop or slow down symptoms.
There are several side effects associated with the therapy, thus impacting the growth of the market.Antiretroviral drugs market are increasingly implementing multi-class combination products for treatment of anti-retroviral therapy.
Example for multiclass combination drugs or single-tablet regimens (STRs), include both NRTIs and NNRTIs: doravirine, lamivudine, and tenofovir disoproxil fumarate (Delstrigo).
Market HighlightsA number of devices for testing the glucose level in the blood are available in the market such as invasive glucose monitoring devices, continuous glucose monitoring devices (CGM), and flash glucose monitoring devices.
These devices are designed according to the type of diabetes, which help to identify the blood glucose level within the specified target range and hence help you to track your diet accordingly.
Growing awareness regarding the devices in developing countries has fueled the demand for these devices in Asia Pacific region.According to the American Diabetes Association, the blood glucose levels for an adult without diabetes is below 100 mg/dl before meals and fasting, and is less than 140 mg/dl two hours after a meal.Request Sample copy:https://www.marketresearchfuture.com/sample_request/632Diabetes is one of the leading causes of premature death and disability.
It can be managed effectively if it diagnosed at early stage.
However, if left untreated, it can lead to various complications such as heart disease, stroke, kidney damage, and nerve damage.The Asia Pacific blood glucose monitoring market is expected to grow at a CAGR of 10% during the forecast period 2017-2021.Regional AnalysisChina dominates the Asia Pacific blood glucose monitoring market owing to well-developed technology, increasing patient population with diabetes, high health care spending, and increasing government support for research & development.
According to WHO, 110 million people have with diabetes in China.India is the second leading country having a large number of diabetic patient population in Asia Pacific.
The growth of this market is mainly driven by increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, rising awareness, and adoption of preventive healthcare approaches, implementation of favorable government initiatives to promote renal health, rapid growth in the geriatric population, and increasing number of drug development initiatives.This report segments the creatinine measurement market on the basis of type, type of sample, end-user, product, and region.
By type, the market is segmented into Jaffe’s kinetic method and enzymatic method.
In 2018, Jaffe’s kinetic method segment is estimated to account for the largest share of the creatinine measurement market, as it is the oldest and most conventional method for creatinine measurement in clinical samples.
Additionally, the widespread availability and cost-effectiveness of kits and reagents used in Jaffe’s kinetic method is another major factor responsible for the large share of this segment.Based on the type of sample, the market is segmented into blood/serum and urine samples.
The blood sample segment accounted for the largest share of the creatinine measurement market in 2017 due to the increased accuracy and low risk of contamination.
This segment is also expected to witness the highest growth over the forecast period, as it is the most preferred sample type for accurate measurement of creatinine levels.For More Information Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=206847385 The diagnostic laboratories segment is expected to witness the highest growth over the forecast period as various market players are entering into long-term collaborations with diagnostic laboratories in order to increase their presence in the creatinine measurement market.
